ReviewMolecular genetics & genomic medicine2025
Expanding the Clinical and Genetic Spectrum of Mitochondrial Short-Chain Enoyl-CoA Hydratase 1 Deficiency: Insights From Two Unrelated Chinese Families.
Review in Molecular genetics & genomic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMitochondrial short-chain enoyl-CoA hydratase 1 deficiency (ECHS1D) is a rare autosomal recessive disorder affecting valine metabolism, with clinical severity ranging from neonatal death to survival into adulthood. Despite advances in understanding ECHS1D, the genetic basis remains underexplored, particularly in underrepresented populations.
methodsThis study aimed to investigate the clinical and genetic characteristics of ECHS1D in two unrelated Chinese families and identify novel pathogenic variants. Clinical and genetic data were collected, and whole-genome sequencing was performed to identify pathogenic variants in the ECHS1 gene.
resultsThe first proband, a 15-month-old girl, presented with developmental delays and metabolic acidosis, with an MRI revealing abnormal signals in the basal ganglia. The second proband, a 6.5-year-old girl with movement-induced dystonia, exhibited lethargy following recurrent fever and vomiting, with similar MRI findings. Genetic testing identified novel compound heterozygous variants: c.759_762del (p.Gly255Valfs*21) and c.489G>A (p.Pro163=) in Proband 1 and c.518C>T (p.Ala173Val) and c.244G>A (p.Val82Met) in Proband 2. The c.759_762del (p.Gly255Valfs21) variant, identified for the first time, likely results in severe symptoms due to a loss of normal function.
conclusionThese findings expand the ECHS1 mutational spectrum and emphasize the importance of genetic testing for early diagnosis and personalized management of ECHS1D. Interventions such as dietary valine restriction and the avoidance of triggering factors may improve clinical outcomes, while further research is needed to explore targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.